Stockscreener 앱 받기
0.00
100.00%
-90.00
시간 외 거래:
88.97
88.97
+
전일 마감가:
$90.00
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$6.83B
수익:
$35.93M
순이익/손실:
$-244.56M
주가수익비율:
0.00
EPS:
-3.95
순현금흐름:
$-157.31M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$97.14
Merus N V Stock (MRUS) Company Profile
명칭
Merus N V
전화
31 030 253 8800
주소
YALELAAN 62, 3584 CM UTRECHT
MRUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
0.00 | 6.83B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-08-25 | 개시 | Alliance Global Partners | Buy |
| 2025-02-13 | 개시 | Piper Sandler | Overweight |
| 2025-02-07 | 개시 | Wells Fargo | Overweight |
| 2024-11-21 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-03-28 | 개시 | Truist | Buy |
| 2024-03-04 | 재확인 | Needham | Buy |
| 2023-11-02 | 개시 | Canaccord Genuity | Buy |
| 2023-08-21 | 개시 | TD Cowen | Outperform |
| 2022-08-02 | 개시 | Stifel | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Needham | Buy |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-06-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-08 | 개시 | William Blair | Outperform |
| 2021-03-16 | 개시 | SVB Leerink | Outperform |
| 2020-06-26 | 개시 | H.C. Wainwright | Buy |
| 2020-05-27 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | 재개 | Guggenheim | Buy |
| 2019-06-28 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 재개 | Guggenheim | Buy |
| 2019-04-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-03-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-12-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2016-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-06-13 | 개시 | Citigroup | Buy |
| 2016-06-13 | 개시 | Guggenheim | Buy |
| 2016-06-13 | 개시 | Wedbush | Outperform |
모두보기
Merus N V 주식(MRUS)의 최신 뉴스
Merus N.V. (MRUS) Stock Analysis: Exploring a 7.78% Potential Upside Amid Biotech Innovations - DirectorsTalk Interviews
Genmab Announces $2.5 Billion Note Offering for Merus Acquisition - MSN
What analysts say about Merus NV stockTrading Volume Surges & Outstanding Investment Returns - earlytimes.in
Retail Trends: How Merus NV 2GH stock moves in volatile trading sessionsProduct Launch & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Why retail investors favor Merus N.V. stockEconomic Indicators Overview & Low Risk Capital Growth Plans - bollywoodhelpline.com
Moody Aldrich Partners LLC Reduces Position in Merus N.V. $MRUS - MarketBeat
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus - ts2.tech
Insider Buying: Merus (NASDAQ:MRUS) Major Shareholder Acquires 2,978 Shares of Stock - MarketBeat
Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout - ts2.tech
Genmab completes acquisition of Merus and delists shares from Nasdaq By Investing.com - Investing.com Australia
Merus Completes Genmab Acquisition and Delists From Nasdaq - TipRanks
Genmab completes acquisition of Merus and delists shares from Nasdaq - Investing.com
Merus Announced Transfer or Voluntary Withdrawal of Listing - TradingView — Track All Markets
Simplify Asset Management Inc. Takes $3.14 Million Position in Merus N.V. $MRUS - MarketBeat
Merus (NASDAQ:MRUS) Major Shareholder A/S Genmab Acquires 96,082 Shares - MarketBeat
Insider Buying: Merus (NASDAQ:MRUS) Major Shareholder Acquires 142,610 Shares of Stock - MarketBeat
A/S Genmab Purchases 561,042 Shares of Merus (NASDAQ:MRUS) Stock - MarketBeat
Insider Buying: Merus (NASDAQ:MRUS) Major Shareholder Purchases 15,710 Shares of Stock - MarketBeat
Merus (NASDAQ:MRUS) Stock Price Down 7%Here's Why - MarketBeat
Fed Watch: Why Merus NV 2GH stock stays undervaluedLong Setup & Weekly Breakout Watchlists - moha.gov.vn
Merus N.V. (NASDAQ:MRUS) Sees Large Decrease in Short Interest - MarketBeat
Stock Traders Buy High Volume of Call Options on Merus (NASDAQ:MRUS) - MarketBeat
Harbor Capital Advisors Inc. Trims Stock Holdings in Merus N.V. $MRUS - MarketBeat
Revenue per share of Merus N.V. – FWB:2GH - TradingView — Track All Markets
GENMAB AS Insider Trades - Nasdaq
A/S Genmab Acquires 66,264 Shares of Merus (NASDAQ:MRUS) Stock - MarketBeat
Merus N.V. $MRUS Stock Position Decreased by Voya Investment Management LLC - MarketBeat
A/S Genmab Acquires 212,177 Shares of Merus (NASDAQ:MRUS) Stock - MarketBeat
How Merus N.v. (MRUS) Affects Rotational Strategy Timing - Stock Traders Daily
MRUS SEC FilingsMerus 10-K, 10-Q, 8-K Forms - Stock Titan
Will Merus N.V. stock maintain dividend yieldJuly 2025 Volume & Verified Stock Trade Ideas - Улправда
Is Merus N.V. (2GH) stock positioned for digital growth eraMarket Performance Summary & Stepwise Swing Trade Plans - Улправда
Will Merus N.V. stock maintain momentum in 2025Weekly Profit Summary & Stock Portfolio Risk Control - Улправда
How Merus N.V. (2GH) stock stacks up against competitorsQuarterly Earnings Report & Free Community Consensus Stock Picks - Улправда
How Merus N.V. (2GH) stock trades in high volatilityPrice Action & Advanced Technical Analysis Signals - DonanımHaber
How cyclical is Merus N.V. (2GH) stock compared to rivalsJuly 2025 Update & Advanced Swing Trade Entry Alerts - Улправда
Insider Buying: Merus (NASDAQ:MRUS) Major Shareholder Buys 150,795 Shares of Stock - MarketBeat
Owner Genmab A/S Buys 271,547 ($26.3M) Of Merus NV [MRUS] - TradingView — Track All Markets
Genmab (GMAB) reports 94.2% ownership of Merus at $97 per share - Stock Titan
A/S Genmab Purchases 120,752 Shares of Merus (NASDAQ:MRUS) Stock - MarketBeat
Sanders Morris Harris LLC Buys Shares of 24,870 Merus N.V. $MRUS - MarketBeat
Merus N.V.(NasdaqGM: MRUS) dropped from S&P Global BMI Index - marketscreener.com
Merus (NASDAQ:MRUS) Sets New 12-Month HighShould You Buy? - MarketBeat
Merus NV stock hits all-time high at 96.95 USD By Investing.com - Investing.com South Africa
Merus NV stock hits all-time high at 96.95 USD - Investing.com
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Benzinga
Revenue per share of Merus N.V. – LSX:A2AKFX - TradingView — Track All Markets
Merus acquired by Genmab, leadership changes announced - MSN
Holocene Advisors LP Boosts Position in Merus N.V. $MRUS - MarketBeat
Boothbay Fund Management LLC Grows Holdings in Merus N.V. $MRUS - MarketBeat
Merus N.V. (NASDAQ:MRUS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Merus N V (MRUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):